share_log

昆药集团获德邦证券买入评级,针剂拖累表观业绩,口服核心品种表现亮眼

JRJ Finance ·  Aug 27, 2024 00:07  · Ratings

8月27日,昆药集团获德邦证券买入评级,近一个月昆药集团获得8份研报关注。

研报预计24-26年归母净利润为5.4/6.8/8.8亿元。研报认为,24H1,受业务结构持续优化及针剂业务因相关政策影响收入有所下滑影响,公司表观业绩承压。24H1,受益于品牌打造与纯销攻坚,公司血塞通软胶囊销售创下近年同期历史新高。未来,圣火“理洫王”凭借其优秀的学术能力、临床证据主打院内,昆药“络泰”规格剂型丰富主打院外,共同谱写银发健康产业发展的全新篇章。

风险提示:集采续约进度不及预期,行业重大政策变更,市场竞争加剧风险等。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment

    Statement

    This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.